In sharp contrast to the branded pharmaceutical market, which has stalled in recent year, the generics market is enjoying a period of unprecedented success. In 2005 the world generics market was worth $45bn, a growth of 14% on the previous year. Visiongain expects this level of growth to continue over the forecast period of this report.

The loss of patent protection by 2009 of almost $80bn worth of top selling drugs will be the major driving force for this generic market growth. Additionally, as healthcare costs in the developed world continue to increase, and the growth of pharmaceutical markets in developing countries continues to grow. More generic copies of successful drugs are being sold worldwide than ever before. This report describes how this burgeoning market will change over the forecast period and highlights the important issues for both originator companies and generic drugs manufacturers.

What is the therapeutic area with the most potential for generic companies? How are branded pharmaceutical companies preparing for the increasing threat of generic penetration? What challenges do generic companies face in the coming years? Read visiongain's The World Generics Market 2006-2011 report to find out.

The following issues are covered in detail:

· A summary of the relevant legislation affecting the generics industry · A market forecast for the world generics market 2006-2011 · An assessment of the drivers and restraints of the market during this period · A discussion of the attitudes to generics in different regions including the US, Europe and Asia · The issue of Biogenerics and the changes in regulations required for their success · A review of strategies for success for originator and generics companies

Why should you buy this report?

The progress of the generic pharmaceutical market is of great importance to anyone in the pharmaceutical industry. This report provides detailed financial data and invaluable opinion about how this market will change over the important period to come.

Companies Mentioned in this report:

Abbott
Actavis
Alpharma
Amgem
Andrx
Apotex
Astellas
AstraZeneca
Azko Nobel
Barr
Biogen Idec
Bristol-Myers-Squibb
Cipla
Dr Reddy’s
Eli Lilly
Forest Laboratories
Genentech
Genzyme Transgenics
GlaxoSmithKline
GTC Biotherapeutics
IVAX
Johnson and Johnson
Lunbeck A/S
Merck
Mylan Laboratories
Nicholas Piramal
Novartis
Pentech
Pfizer
Pliva
Rambaxy
Roche
Sandoz
Sanofi-Aventis
Schering-Plough
Schwarz Pharma
Sicor
Synthon Pharmaceuticals
Teva
TranXenoGen
Viragen
Watson Pharmaceuticals
Wyeth